

## Be on the Lookout for Kratom! References

- Alsarraf E, Myers J, Culbreth S, Fanikos J. Kratom from head to toe – case reviews of adverse events and toxicities. *Curr Emerg Hosp Med Rep.* 2019;7:141-68. doi:10.1007 /s40138-019-00194-1
- Bell C, Baca D Jr. A Leaf of Faith [Documentary]. United States: 1091 Pictures; 2018.
- Cohen P. High-risk dietary supplements: Patient evaluation and counseling. Seres D and Hendrickson R, eds. UptoDate. Waltham, MA: UptoDate Inc. <https://www.uptodate.com>. Accessed March 7, 2023.
- Garcia-Romeu A, Cox DJ, Smith KE, Dunn KE, Griffiths RR. Kratom (*Mitragyna speciosa*): user demographics, use patterns, and implications for the opioid epidemic. *Drug Alcohol Depend.* 2020 Mar 1; 208:107849. Doi:10.1016/j.drugalcdep.2020.107849
- Garmon EH, Olson K. Narrative review of kratom, an emerging psychoactive substance with perianesthetic implications. *Anesth Analg.* 2022;135(6):1180-1188. doi:10.1213/ANE.0000000000006177
- Gorelick DA. Kratom: Substance of abuse or therapeutic plant?. *Psychiatr Clin North Am.* 2022;45(3):415-430. doi:10.1016/j.psc.2022.04.002
- Grundmann O, Hendrickson RG, Greenberg MI. Kratom: History, pharmacology, current user trends, adverse health effects and potential benefits [published online ahead of print, 2022 Jun 19]. *Dis Mon.* 2022;101442. doi:10.1016/j.disamonth.2022.101442
- Guddat S, Görgens C, Steinhart V, Schänzer W, Thevis M. Mitragynine (kratom) – monitoring in sports drug testing. *Drug Test Anal.* 2016;8(11-12):1114-1118. doi:10.1002/dta.1970
- H 3742, 2023-2024, Session 125 (SC 2023). In Committee as of 5/18/2023. <https://www.scstatehouse.gov/billsearch.php?billnumbers=3742&session=125&summary=B>
- Hartley C 2nd, Bulloch M, Penzak SR. Clinical pharmacology of the dietary supplement kratom (*Mitragyna speciosa*). *J Clin Pharmacol.* 2022 May;62(5):577-593. doi: 10.1002/jcph.2001. Epub 2022 Jan 5. PMID: 34775626.
- Harun N, Kamaruzaman NA, Mohamed Sofian Z, Hassan Z. Mini review: Potential therapeutic values of mitragynine as an opioid substitution therapy. *Neurosci Lett.* 2022;773:136500. doi:10.1016/j.neulet.2022.136500
- HB 551, 2019-2020 Regular Session (GA 2019). Effective Date 4/26/2019. <https://www.legis.ga.gov/legislation/55621>
- HB 563, 2023-2024, 2023 Session (NC 2023). In Committee as of 5/18/2023. <https://www.ncleg.gov/BillLookUp/2023/hb563>
- Hoffman RJ. Testing for drugs of abuse. Schwarz E, ed. UpToDate. Waltham, MA: UpToDate Inc. <https://www.uptodate.com>. Accessed April 25, 2023.
- Jentsch MJ, Pippin MM. Kratom. [Updated 2023 Jan 23]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK585120/>
- Larsen I, Zhang E, Farahmand P. Current understanding of the effects and potential clinical utility of kratom: A review. *J Psychiatr Pract.* 2022;28(2):92-97. doi:10.1097/PRA.000000000000609
- Legislative Analysis and Public Policy Association. Kratom: Summary of state laws. <http://legislativeanalysis.org/wp-content/uploads/2022/12/Kratom-Summary-of-State-Laws.pdf>. December 2022.

## Be on the Lookout for Kratom! References

Natural Medicines. Commercial products containing kratom. Stockton, CA: Therapeutic Resource Center. 2023. Available from: [https://naturalmedicines.therapeuticresearch.com/databases/commercial-products.aspx?monograph=1513&letter=\\_&sort-asc=0&sort-field=Nmber](https://naturalmedicines.therapeuticresearch.com/databases/commercial-products.aspx?monograph=1513&letter=_&sort-asc=0&sort-field=Nmber). Accessed January 26, 2023.

Natural Medicines. Kratom professional monograph. Stockton, CA: Therapeutic Resource Center. June 28, 2022. Available from: <https://naturalmedicines.therapeuticresearch.com/databases/food,-herbs-supplements/professional.aspx?productid=1513#products>. Accessed February 8, 2023.

NIDA. Kratom. National Institute on Drug Abuse website. <https://nida.nih.gov/research-topics/kratom>. March 25, 2022. Accessed May 5, 2023.

Office of the Commissioner. FDA issues warnings to companies selling illegal, unapproved kratom drug products marketed for opioid cessation, pain treatment and other medical uses. U.S. Food and Drug Administration. Published 2019. <https://www.fda.gov/news-events/press-announcements/fda-issues-warnings-companies-selling-illegal-unapproved-kratom-drug-products-marketed-opioid>. Accessed Feb 8, 2023.

Office of the Commissioner. FDA Roundup: July 5, 2022. FDA. Published July 5, 2022. Accessed Feb 8, 2023. <https://www.fda.gov/news-events/press-announcements/fda-roundup-july-5-2022>

Prevete E, Kuypers KPC, Theunissen EL, Corazza O, Bersani G, Ramaekers JG. A systematic review of (pre)clinical studies on the therapeutic potential and safety profile of kratom in humans. *Hum Psychopharmacol*. 2022;37(1):e2805. doi:10.1002/hup.2805

Saper RB. Overview of herbal medicine and dietary supplements. Elmore JG and Seres D, eds. UptoDate. Waltham, MA: UptoDate Inc. <https://www.uptodate.com>. Accessed April 25, 2023.

Sevarino KA. Medically supervised opioid withdrawal during treatment of addiction. Friedman M, Ed. UpToDate. Waltham, MA: UptoDate Inc. <https://www.uptodate.com>. Accessed April 25, 2023.

Sharma R, Barnes J. Charms and harms: Kratom. *J Prim Health Care*. 2022;14(3):288-290. doi:10.1071/HC22110

Smith KE, Dunn KE, Rogers JM, Garcia-Romeu A, Strickland JC, Epstein DH. Assessment of kratom use disorder and withdrawal among an online convenience sample of US adults. *J Addict Med*. 2022;16(6):66-70. doi:10.1097 / ADM.0000000000000986

Stanciu C, Ahmed S, Gnanasegaram S, et al. Kratom as an opioid alternative: Harm, or harm reduction? A systematic review of literature. *Am J Drug Alcohol Abuse*. 2022;48(5):509-528. doi:10.1080/00952990.2022.2111685

Stanciu C, Ahmed S, Hybki B, Penders T, Galbis-Reig D. Pharmacotherapy for management of 'kratom use disorder': A systematic literature review with survey of experts. *WMJ*. 2021;120(1):54-61.

Statement from FDA Commissioner Scott Gottlieb, M.D., on the agency's scientific evidence on the presence of opioid compounds in kratom, underscoring its potential for abuse. FDA. Published March 24, 2020. <https://www.fda.gov/news-events/press-announcements/statement-fda-commissioner-scott-gottlieb-md-agencys-scientific-evidence-presence-opioid-compounds>. Accessed Feb 8, 2023.

Swogger MT, Smith KE, Garcia-Romeu A, et al. Understanding kratom use: a guide for healthcare providers. *Front Pharmacol*. 2022;13:801855. doi:10.3389/fphar.2022.801855

Test 791750: Kratom (Mitragynine), screen and confirmation, urine | Labcorp. [www.labcorp.com](http://www.labcorp.com). <https://www.labcorp.com/tests/791750/kratom-mitragynine-screen-and-confirmation-urine>. Accessed May 2, 2023.

US Drug Enforcement Administration. Kratom: Drug fact sheet. <https://www.dea.gov/sites/default/files/2023-04/Kratom%202022%20Drug%20Fact%20Sheet.pdf>. October 2022.

Weiss ST, Douglas HE. Treatment of kratom withdrawal and dependence with buprenorphine/naloxone: a case series and systematic